1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,694 | 1,722 | 09:47 | |
| 1,692 | 1,730 | 09:44 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.06. | SynAct Pharma AB: BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study | 347 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through resolution therapy, today provides an update following... ► Artikel lesen | |
| 15.06. | SynAct Pharma AB: Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering | 289 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, reported today that resomelagon in combination... ► Artikel lesen | |
| 12.06. | SynAct Pharma AB: SynAct obtains key US patent for resomelagon securing exclusivity until 2044 | 254 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the United States Patent and Trademark Office (USPTO) have provided the issue notification of US patent 12,661,336 with issue date 23 June 2026... ► Artikel lesen | |
| 11.06. | SynAct Pharma AB: Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ) | 304 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) held its Annual General Meeting today, Thursday 11 June 2026, at the offices of MAQS Advokatbyrå in Stockholm. Attorney Eric Ehrencrona from MAQS Advokatbyrå was elected as chairman... ► Artikel lesen | |
| 27.05. | SynAct Pharma AB: SynAct Pharma publishes Q1 2026 interim results | 277 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2026.
"As we close the first quarter of 2026, SynAct Pharma is in a stronger position than at any previous... ► Artikel lesen | |
| 06.05. | SynAct Pharma AB: SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study | 501 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully completed dosing... ► Artikel lesen | |
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.03. | SynAct Pharma AB: SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon | 241 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dosed... ► Artikel lesen | |
| 03.03. | SynAct Pharma - Multiple shots on goal in 2026 for resomelagon | 449 | Edison Investment Research | SynAct Pharma's FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment... ► Artikel lesen | |
| 24.02. | SynAct Pharma AB: SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer | 191 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Ann Kristin... ► Artikel lesen | |
| 18.02. | SynAct Pharma AB: SynAct Pharma Year-end Report 2025 | 215 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025
"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical... ► Artikel lesen | |
| 10.02. | SynAct Pharma - Resomelagon progresses in RA, viral infections | 483 | Edison Investment Research | SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency... ► Artikel lesen | |
| 06.02. | SynAct Pharma AB: SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study | 423 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully reached the recruitment... ► Artikel lesen | |
| 30.01. | SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency | 394 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initiated... ► Artikel lesen | |
| 19.01. | SynAct Pharma AB: SynAct Pharma appoints Malin Wikstrand as interim CFO | 225 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announces that Malin Wikstrand... ► Artikel lesen | |
| 27.11.25 | SynAct Pharma AB: Report from the Extraordinary General Meeting of SynAct Pharma AB | 290 | GlobeNewswire (Europe) | An Extraordinary General Meeting in SynAct Pharma AB (publ) was held today, 27 November 2025, at MAQS Advokatbyrå's premises at Stureplan 19 in Stockholm. Chairperson of the General Meeting was Matilda... ► Artikel lesen | |
| 03.11.25 | SynAct Pharma AB: Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion | 341 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has randomized 190 out of 240 patients... ► Artikel lesen | |
| 31.10.25 | SynAct Pharma - Approaching a catalyst-rich period | 413 | Edison Investment Research | SynAct Pharma's Q325 results underscored the company's steady progress on its clinical strategy, led by the ongoing Phase IIb ADVANCE trial evaluating resomelagon as a first-line treatment for rheumatoid... ► Artikel lesen | |
| 30.10.25 | SynAct Pharma AB: SynAct Pharma publishes Q3 2025 interim results | 235 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the third quarter 2025.
"SynAct is in a fortunate position now as the company has two development tracks, across both autoimmune... ► Artikel lesen | |
| 28.10.25 | SynAct Pharma - Differentiated inflammation resolution approach | 379 | Edison Investment Research | SynAct Pharma is focused on inflammation resolution therapeutics. Its lead asset, resomelagon, is differentiated by its novel mechanism, targeting specific melanocortin receptor subtypes believed to... ► Artikel lesen | |
| 16.09.25 | SynAct Pharma AB: SynAct Pharma's CFO Björn Westberg leaves for new leading position | 224 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that the company's... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 53,16 | -0,37 % | Märkte am Morgen: Öl, Alphabet, Bayer, Rheinmetall, Zalando, Allianz, Munich Re | Der DAX hat eine schwache Woche hinter sich. Speziell am Freitag ging es noch einmal deutlich nach unten. Der Leitindex schloss bei 24.671 Punkten. Das ist auf Tagesbasis ein Minus von rund 1,3 Prozent.... ► Artikel lesen | |
| ABBVIE | 227,20 | +0,13 % | Starkes Studiensignal: Positive Wende für AbbVie: Neues Blockbuster-Medikament vor Zulassung | © Foto: SOPA Images - picture alliance / Sipa USAAbbVie hat eine wichtige Empfehlung der europäischen Arzneimittelbehörde erhalten. Damit rückt eine neue Therapie gegen schweren Haarausfall näher.Der... ► Artikel lesen | |
| ELI LILLY | 1.064,80 | +0,93 % | KI- und Übernahme-Wirbel im LifeScience-Sektor! Bayer, Vidac Pharma, Novo Nordisk, Evotec und Eli Lilly | Ja, Sie haben richtig gelesen. Pharmakonzerne setzen aktiv auf Künstliche Intelligenz (KI) und könnten so mit geringeren Kosten, besseren Validierungen und schnelleren Studien-SetUps mittelfristig zu... ► Artikel lesen | |
| MERCK & CO | 113,76 | +0,99 % | DAX vor festem Start: Hoffnungen auf Deeskalation stabilisieren die Börsen, Öl legt zu, Gold sackt ab | © Foto: Arne Dedert/dpaNachdem sich die USA und Iran auf ein Ende der Kampfhandlungen geeinigt haben, deutet sich an den europäischen und US-Börsen ein fester Handelsstart an. Der Ölpreis steigt, Gold... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 50,45 | -0,10 % | Novartis, Gilead Sciences und Co. investieren Milliarden - warum jetzt die nächste Generation der Zelltherapie beginnt | ||
| INNOCAN PHARMA | 2,000 | +9,59 % | EILMELDUNG bei InnoCan Pharma: Was Insider heute bereits wissen - Meine klare Einschätzung dazu | ||
| DOCMORRIS | 10,180 | +1,19 % | DocMorris-Aktie: Ist der Sprung über 10 Franken gerechtfertigt? | Die Schweizer Versandapotheke DocMorris rückt wieder stärker in den Fokus der Anleger. Allein im Juni legte die DocMorris-Aktie um rund +26% zu. Am Mittwoch verbessert sie sich aktuell um +2,8% und... ► Artikel lesen | |
| INCYTE | 103,45 | +0,88 % | INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura | ||
| SINOPHARM | 1,941 | +3,41 % | Dividendenbekanntmachungen (23.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADAMAS TRUST INC US6496048405 0,27 USD 0,2362 EUR AECON GROUP INC CA00762V1094 0,1925 CAD 0,1189 EUR AMPHENOL CORPORATION US0320951017 0... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,020 | +3,55 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Rosie's Burgers Secures Greater Montreal's First South Shore Real-Estate Location in Longueil's Greenfield Park, Quebec | Toronto, Ontario--(Newsfile Corp. - June 22, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| COMPASS PATHWAYS | 12,400 | -0,80 % | Psychedelika-Boom 2.0: Während US-Riesen mit Milliarden bewertet werden, liefert dieser australische Spezialist bereits Daten | ||
| HIGH TIDE | 1,982 | -0,90 % | Remexian Pharma, deutsche Tochtergesellschaft von High Tide, präsentiert exklusive Partnerschaften mit kanadischen medizinischen Cannabismarken bei Mary Jane Berlin 2026 | CALGARY, AB / 17. Juni 2026 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen") (NASDAQ: HITI) (TSXV: HITI) (FWB: 2LYA), das hochdynamische, auf
den Einzelhandel ausgerichtete Unternehmen... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 214,20 | -0,33 % | AbCellera Biologics Inc.: Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies | The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 278,00 | -1,42 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 13,150 | +1,54 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen |
SYNACT PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -1,18 % bei einem Aktienkurs von 1,672 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.